- Novo Nordisk presented four analyses on oral semaglutide 25 mg at ObesityWeek 2025.
- Analyses showed improvements in blood sugar control and cardiovascular risk factors.
- Oral semaglutide 25 mg showed comparable efficacy to the injectable form.
- Weight loss efficacy was consistent in women with obesity, regardless of menopausal stage.
Overview of Analyses
Novo Nordisk presented four new analyses on oral semaglutide 25 mg at ObesityWeek 2025. These analyses are part of the OASIS 4 phase 3 trial, which explored various patient groups and hypotheses.
Blood Sugar and Cardiovascular Improvements
The post hoc analyses demonstrated that oral semaglutide 25 mg was associated with improvements in blood sugar control and cardiovascular risk factors across multiple weight loss categories.
Comparison with Injectable Form
One analysis provided an indirect trial comparison between oral semaglutide 25 mg and the currently available injectable form, showing comparable efficacy between the two.
Weight Loss Efficacy in Women
Two additional analyses highlighted that oral semaglutide 25 mg maintained the same weight loss efficacy in women with obesity, regardless of their menopausal stage. Patients also reported improvements in physical function.
